Artelo Biosciences Inc
Company Profile
Business description
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Contact
505 Lomas Santa Fe
Suite 160
Solana BeachCA92075
USAT: +1 858 925-7049
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
Wide moat share expects luck to turn
stocks
ASX share’s growth story intact despite supply constraints
stocks
ASX healthcare giant rallies despite a fall in profits
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,269.70 | 13.70 | -0.15% |
| CAC 40 | 8,484.43 | 31.34 | 0.37% |
| DAX 40 | 26,136.56 | 153.52 | 0.59% |
| Dow JONES (US) | 53,277.01 | 517.80 | 0.98% |
| FTSE 100 | 10,816.56 | 68.40 | 0.64% |
| HKSE | 26,009.46 | 310.97 | 1.21% |
| NASDAQ | 26,180.46 | 113.29 | 0.43% |
| Nikkei 225 | 66,016.36 | 200.43 | -0.30% |
| NZX 50 Index | 13,972.66 | 52.84 | 0.38% |
| S&P 500 | 7,674.37 | 33.21 | 0.43% |
| S&P/ASX 200 | 9,058.90 | 6.90 | -0.08% |
| SSE Composite Index | 3,905.20 | 1.48 | 0.04% |